Deciphera Pharmaceuticals and Zai Lab, a China/US-based biopharma, will together advance the development and commercialisation of ripretinib in Greater China.
Discovered and developed by Deciphera, ripretinib is an investigational, oral, kinase switch control inhibitor in clinical development for the treatment of GIST and other solid tumours driven by KIT or PDGFRα.
As per the agreement, Deciphera will receive an upfront cash payment of $20 million and will be eligible to receive up to $185 million in potential development and commercial milestone payments.
Additionally, Zai Lab would pay Deciphera royalties from low to high teens on annual net sales of ripretinib in Greater China.
Zai Lab receives exclusive regional development and commercialization rights for ripretinib in Greater China.
The company said it plans to leverage its regulatory and clinical expertise to lead development of ripretinib in this territory.
Deciphera intends to expand the ongoing global Phase 3 INTRIGUE study, comparing ripretinib to sunitinib in second-line GIST patients, and is currently assessing the addition of clinical trial sites in China.